There is a lot going on at Sanofi with a variety of streamlining and restructuring measures. At the heart of these initiatives is a plan to provide a significant cash pile to drive a new generation of immunology products to build on its leadership in the space on the back of the success of mega-blockbuster Dupixent.
Barely a day goes by without news of changes at the French drugmaker. The last couple of weeks have seen announcements concerning the restructuring of its US vaccine commercial operations, plans to divest the assets of Amunix Pharmaceuticals, Inc., an immuno-oncology specialist Sanofi acquired in 2022 for $1bn, and the closure of Dutch natural killer cell therapy firm Kiadis Pharma NV, bought back in 2021